A new validated RP-HPLC method for the determination of Tinidazole and Roxithromycin in its bulk and pharmaceutical dosage forms

To develop and validate a novel reverse-phase high-performance liquid chromatography determination of Tinidazole and Roxithromycin in its Bulk and Pharmaceutical Dosage Forms. Examination of simultaneous determination is centered around the advancement of novel RP-HPLC systematic technique for the assurance of medication substance in strong oral dose shapes and their approval. The optimized chromatographic condition was established for the estimation of Tinidazole and Roxithromycin by using Agilent C18 (4.6 X 250mm, 5 µm) column, sodium acetate buffer (pH 3) and Methanol (30:70% v/v) as mobile phase at a flow rate of 1.0 ml/min sustain an ambient temperature. The total analysis time was 10 minutes and the retention of Tinidazole and Roxithromycin was found to be 2.352 and 5.941 min with an injection volume of 20 µl. The system suitability parameters proved for optimized chromatographic conditions for Tinidazole and Roxithromycin were within limits. The developed method was showing good resolution and separation factors.